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Background: This study investigated the effect of transcriptional gene silencing (TGS) of the heparanase gene on
hepatoma SMCC-7721 cells.
Methods: SiRNAs targeting the promoter region and coding region of the heparanase gene were designed and
synthesized. Then the siRNAs were transfected into hepatoma SMCC-7721 cells by nuclear transfection or cytoplasmic
transfection. The expression of heparanase was detected by RT-PCR and Western blotting 48 h, 72 h and 96 h
post-transfection. In addition, wound healing and invasion assays were performed to estimate the effect of TGS
of the heparanase gene on the migration and invasion of hepatoma SMCC-7721 cells.
Results: Protein and mRNA expression of the heparanase gene were interfered with by TGS or post-transcriptional
gene silencing (PTGS) 48 h after transfection. At 72 h post-transfection, the expression of the PTGS group of genes had
recovered unlike the TGS group. At 96 h post-transfection, the expression of the heparanase gene had recovered in
both the TGS group and PTGS group. Invasion and wound healing assays showed that both TGS and PTGS of the
heparanase gene could inhibit invasion and migration of hepatoma SMCC-7721 cells, especially the TGS group.
Conclusions: TGS can effectively interfere with the heparanase gene to reduce the invasion and migration of
hepatoma SMCC-7721 cells.
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The heparanase gene is located on human chromosome
4q 21.3, which contains a CpG island at the 5′ end of
the promoter region, indicating that expression of hepa-
ranase is regulated by epigenetic mechanisms such as
methylation [1]. High levels of heparanase have been re-
ported for hepatic carcinoma, breast cancer, colorectal
cancer, lung cancer and lymphoma [2-4], and are in-
volved in tumor metastasis and invasion [5-7]. On the
other hand, inhibition of expression of heparanase has
been reported to have an inhibitory effect on cancer in-
vasion and metastasis. Zheng et al. reported that small* Correspondence: w_hxiao@hotmail.com
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reproduction in any medium, provided the orRNA interference-mediated gene silencing of heparanase
could inhibit the invasion, metastasis and angiogenesis
of gastric cancer cells [8]. RNA interference (RNAi), a
new technology in molecular biology, has become one of
the most commonly used methods in research into gene
function [9], including transcriptional gene silencing (TGS)
and post-transcriptional gene silencing (PTGS) [10]. In
PTGS, a small molecule RNA (siRNA) is designed for the
coding region of a gene and targets the corresponding
mRNA sequence-specific binding and degradation of the
target sequence, inducing gene silencing [9]. Continuous
activation of upstream gene transcription leads to synthesis
of a large amount of mRNA, which makes it difficult to
maintain the silencing of a gene for a long time. Therefore,
the interference efficiency of PTGS is not high. Previous
studies have found that TGS has a high efficiency in plant
cells, acting through permanent gene silencing by DNAtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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promoter region of DNA. This is called siRNA-direct DNA
methylation or histone modification [11-13]. Kawasaki et al.
[14] have found that this effect of TGS also occurs in human
cells. Theoretically, interfering with a gene using an siRNA
targeting the 5′ end of the promoter region can produce a
long-lasting silence. Therefore, TGS seems more effective
than PTGS with respect to the costs and prospects for
clinical application.
In the present study, siRNA was transfected into hepa-
toma SMCC-7721 cells using TGS and PTGS to inter-
fere with the expression of heparanase. Differences in
the effect and the length of gene silencing were deter-
mined to evaluate the impact of silenced heparanase on
the migration and invasion of SMCC-7721 cells.
Methods
Cell culture
Hepatoma SMCC-7721 cells (a hepatoma cell line) were
purchased from the Institute of Biochemistry and Cell
Biology of the Chinese Academy of Science in Shanghai.
The cells were cultured in DMEM (Gibco, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum
(FBS) (Gibco, Carlsbad, CA, USA) at 37°C, 95% humi-
dity and 5% CO2. The cells were passaged every 3 to
4 days by trypsinization.
Preparation of siRNA and transfection
The complete genome of heparanase (GenBank acces-
sion: [GenBank:NC_010725]) was used to design the
siRNA sequences. Both TGS and PTGS siRNA oligos
were designed and synthesized by Bioo Scientific Cor-
poration (Austin, TX, USA). The sequences were blasted
with the promoter region or mRNA of the genome by
DNAMAN software. The siRNA sequences of the oligos
used in the following experiment were as follows: for
TGS of heparanase: GAGGAAGUGCUAGAGACUCU
and for PTGS of heparanase: CCUUAAGAAGGCU
GAUAUU. Nucleofections were carried out as previously
described by nucleofection with the Nucleofector device
from Amaxa Biosystems (Cologne, Germany) [15]. The
DharmaFECT transfection reagent (Thermo Scientific,
Pittsburgh. PA, USA) was used for transfection of PTGS
according to the manufacturer’s instructions.
RT-PCR
At 48 h, 72 h and 96 h post-transfection, cells were har-
vested and total RNA was extracted using the TRIzol re-
agent (Life Technologies, Carlsbad, CA, USA) according
to the manufacturer’s instructions. Complementary DNA
(cDNA) was obtained by using a reverse transcription kit
(Fermentas, Pittsburgh. PA, USA). The following primers
were designed for RT-PCR: heparanase: sense: 5′-ATGTG
GAGGAGAAGTTACGG-3′; antisense: 5′-TGAGTTGGACAGATTTGGAA-3′ and β-actin: sense: 5′-CATCCAG
CGTACTCCAAAGA-3′; antisense: 5′-GACAAGTCTGA
ATGCTCCAC-3′. Amplifications were performed with
32 cycles of 30 sec at 94°C, 30 sec at 55°C and 45 sec at
72°C. The PCR product was then assessed by 1.2% agarose
gel electrophoresis and visualized using the Gel Documen-
tation System (BIO-RAD, Hercules, CA, USA). For real-
time quantitative RT-PCR, the following primers for
heparanase were designed: sense: 5′-GTGGTGATGAGG
CAAGTATTC-3′ and antisense: 5′-GTGGTGATGAGG
CAAGTATTC-3′. The mRNA of heparanase was deter-
mined with the EverGreen PCR kit (TransGen Biotech Co,
Ltd, Beijing, China) using real-time RT-PCR (ABI7500,
Carlsbad, CA, USA). The PCR mixture (20 μl final volume
per reaction) was prepared according to the manufacturer′
s protocol. PCR amplifications were performed with 40 cy-
cles of 30 sec of denaturation at 94°C, 45 sec of annealing
at 60°C and 45 sec of elongation at 72°C. Data were ana-
lyzed with the standard 2-△△Ct method and values are
expressed as the average of triplicates.
Western blot
SiRNA-transfected hepatoma SMCC-7721 cells were har-
vested at 48 h, 72 h and 96 h post-transfection. The har-
vested cells were washed and lysed with lysis buffer (0.5%
SDS, 1 mM tris–HCl, 1 mM sodium ortho-vanadate and
protease inhibitor cocktail (Sigma, St. Louis, MO, USA)).
The total protein concentrations were determined with
the Bradford method [16]. An equal amount of protein
from each subject was separated through SDS-PAGE
and subsequently transferred onto PVDF (Polyvinyli-
dene fluoride) membranes. The membranes were blocked
with 5% (w/v) nonfat dry milk in tris-buffered saline with
0.05% Tween 20 for 1 h and followed with 1 h of incuba-
tion with mouse anti-sera against β-actin (1:2,000) or
rabbit anti heparanase (1:500). HRP (horse radish pero-
xidise) -conjugated goat anti-mouse or rabbit immu-
noglobulin G (IgG) (1:1,000) was used as secondary
antibodies and the reactions were detected using a chemilu-
minescence kit (Pierce, Rockford, IL, USA).
Migration assay
To investigate the role of heparanase in the migration of
hepatoma SMCC-7721 cells, a wound-healing test was
performed. Seven groups of cells were used in this ex-
periment: the control cells, TGS transfected cells (48 h,
72 h and 96 h post-transfection) and PTGS transfected
cells (48 h, 72 h and 96 h post-transfection). Transfec-
tion for TGS and PTGS were carried out according to
the process described above. The cells were separately
seeded in 35 mm plates and cultured in DMEM with
10% FBS. A sterile 200 μl pipette tip was used to scratch
the cell monolayers, creating a wound when the cells
reached confluence. Images of the wounds were captured
Figure 1 Gene expression of heparanase in TGS and PTGS
groups. control: untransfected cells; HPSE, heparanase; M: DNA
ladder; PTGS, post-transcriptional gene silencing; PTGS48h: 48 h after
PTGS transfection; PTGS72h: 72 h after PTGS transfection; PTGS96h:
96 h after TGS transfection; TGS, transcriptional gene silencing;
TGS48h: 48 h after TGS transfection; TGS72h: 72 h after TGS transfection;
TGS96h: 96 h after TGS transfection.
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and 96 h post-transfection) after the scratch during wound
healing. Then the images were captured to compare the
migration ability of the cells of each group. All samples for
each group were assayed in duplicate. The experiment
was performed three times.
Invasion assay
To assess the role of heparanase in the invasion of hepa-
toma SMCC-7721 cells, an invasion assay was performed,
using the BD BioCoat Matrigel™ invasion chambers (BD
Biosciences, San Jose, CA, USA) pre-coated with BD
Matrigel matrix (simulating the extracellular matrix) ac-
cording to the manufacturer’s protocol. The medium of
the transfected (TGS and PTGS) or untransfected cells
was replaced with serum-free DMEM medium and cul-
tured for 24 h at 37°C, followed by digestion with 0.25%
trypsin and cell counting. We separately added 5 × 104
control hepatoma SMCC-7721 cells, TGS transfected
hepatoma SMCC-7721 cells and PTGS transfected hepa-
toma SMCC-7721 cells suspended in 100 μl serum-free
DMEM medium onto the apical chambers carefully, and
added 100 μl DMEM medium with 10% FBS to the basal
chambers. If provided with sufficient nutrition, cells in ap-
ical chambers may migrate into the basal chambers. After
24 h of culture at 37°C, the chambers were washed twice
and fixed with 1 ml of formaldehyde for 20 min. Then the
chambers were stained with Gentian violet for 15 min
followed by three washes. The cells were observed and
counted using an inverted microscope (DMI4000B, Leica,
Solms, Germany).
Statistical analysis
Statistical analysis was performed using SPSS 13.0. The
in vitro invasion assay was analyzed using a one-way
ANOVA test. A P value (two-sided) of 0.05 was consi-
dered statistically significant.
Results
Transcriptional gene silencing and post-transcriptional
gene silencing of heparanase mRNA in hepatoma
SMCC-7721 cells
Expression of heparanase mRNA was assessed by RT-
PCR. As shown in Figure 1, the mRNA of the heparanase
gene of the TGS group showed there was successful inter-
ference at 48 h and 72 h post-transfection. Unlike the
TGS group, the heparanase expression of the PTGS group
had recovered at 72 h post-transfection. The heparanase
expression of both TGS and PTGS transfected hepatoma
SMCC-7721 cells had recovered at 96 h post-transfection.
Quantitative RT-PCR gave similar results for the expres-
sion of the heparanase gene: the heparanase gene was
expressed in both the TGS and the PTGS groups and the
level was nearly half that of the control group. Theseresults indicate that both TGS and PTGS of heparanase
can interfere with the expression of heparanase mRNA.
However, silencing of heparanase only lasted for no more
than 72 h using PTGS, indicating a weaker silencing effect
compared with TGS.Transcriptional gene silencing and post-transcriptional
gene silencing of heparanase protein in hepatoma
SMCC-7721 cells
The expression of the heparanase protein was assessed using
Western blotting and the results are shown in Figure 2. The
heparanase expression of the TGS group was successfully in-
terfered with at 48 h and 72 h post-transfection. The hepara-
nase expression of the PTGS group had recovered at 72 h
post-transfection. As with gene expression, the heparanase
protein levels of both TGS and PTGS transfected hepatoma
SMCC-7721 cells had recovered at 96 h post-transfection.
These findings are consistent with those for mRNA
expression.Migration of hepatoma SMCC-7721 cells after transcriptional
gene silencing and post-transcriptional gene silencing of
heparanase
Compared with the control group, the wound gaps of
the TGS group and the PTGS group were more evident
after 48 h and 72 h of migration. On the other hand, the
gaps for both groups became smaller after 24 h of mi-
gration, as bigger and longer cells gathered toward the
gap center (Figure 3). The migration capability of the
two groups of cells was enhanced significantly at 96 h
post-transfection. In combination, these results suggest
that both TGS and PTGS of heparanase gene could inhibit
the migration of hepatoma SMCC-7721 cells. Moreover,
TGS of heparanase had a longer inhibitory effect on cell
migration than PTGS of heparanase.
Figure 2 Protein expression of heparanase in TGS and PTGS groups. (A) Protein expression of heparanase in the TGS and PTGS groups.
(B) Semi-quantitation of heparanase protein in the TGS and PTGS groups. control: untransfected cells; PTGS, post-transcriptional gene silencing;
PTGS48h: 48 h after PTGS transfection; PTGS72h: 72 h after PTGS transfection; PTGS96h: 96 h after TGS transfection; TGS, transcriptional gene silencing;
TGS48h: 48 h after TGS transfection; TGS72h: 72 h after TGS transfection; TGS96h: 96 h after TGS transfection. HPA, heparanase.
Figure 3 Effect of TGS and PTGS of heparanase on migration of SMCC-7721 cells. At 48 h, 72 h and 96 h after TGS or PTGS transfection,
SMCC-7721 cells were seeded in 35 mm plates and scratched. Pictures of the TGS group (A), PTGS group (B) and the control group (C) were
taken 0 h and 24 h after the scratch and the average width of the gaps was then measured (D). *P < 0.05 and **P < 0.01 compared with 0 h.
control: untransfected cells; p.s., post scratch; PTGS, post-transcriptional gene silencing; PTGS48h: 48 h after PTGS transfection; PTGS72h: 72 h
after PTGS transfection; PTGS96h: 96 h after TGS transfection; TGS, transcriptional gene silencing; TGS48h: 48 h after TGS transfection;
TGS72h: 72 h after TGS transfection; TGS96h: 96 h after TGS transfection. (D) Quantitation of the average width of the gaps.
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gene silencing and post-transcriptional gene silencing of
heparanase
At 48 h after TGS and PTGS transfection, 50 and 78
cells, respectively, had passed through the fiber mem-
brane at the bottom of the Transwell chamber. At 72 h
after TGS and PTGS transfection, there were 60 and 88
cells, respectively. For the control group, 100 and 130
cells passed through the Transwell chamber fiber mem-
brane, suggesting there was reduced invasion ability of
the two transfected groups compared with the control
group (Figure 4). At 96 h after transfection, 98 and 100
cells for the TGS and PTGS groups, respectively, had
passed through the membrane. The results were not sig-
nificant compared with the control group (count was
120, P > 0.05). Compared with the TGS group, the inva-
sion ability of the PTGS group was much weaker at 48 h
and 72 h after transfection (Table 1). However, the inva-
sion ability of the TGS and PTGS groups showed no
obvious differences at 96 h after transfection.
Discussion
Invasion and metastasis are the main problems in the
clinical treatment of tumors and heparanase is believed
to play an important role in these processes. Currently,
studies have paid more attention to gene therapy in the
elucidation of the molecular mechanism of cancer. Re-
cently, RNAi has been successfully used to interfere with
the expression of a variety of target genes to inhibit the
growth of different tumor cells. In addition to cancerFigure 4 Effect of TGS and PTGS of heparanase on invasion of SMCC-77
(C) 96 h after TGS transfection. (a) 48 h after PTGS transfection. (b) 72 h after
average width of the gaps. .genes, genes that express anti-apoptotic molecules, te-
lomerase and growth factor receptors as well as some
signaling molecules have also been interfered with in
other anti-tumor studies [17,18]. RNAi has been used to
explore the function and interaction of genes, providing
a convenient way to screen the target genes of new
drugs.
It has been proved that RNAi-induced heparanase silen-
cing can inhibit cell invasion of gastric carcinoma [19], hepa-
tocellular carcinoma [20] and embryonal rhabdomyosarcoma
[21]. Traditional gene-targeting therapy for cancer is at
the post-transcriptional level, silencing the corresponding
mRNA. However, the promoter of the gene is still active,
which creates difficulties in maintaining long-term silen-
cing of the transcription of the target genes. To keep a tar-
get gene silent, the only approach is the continuous
addition of siRNA. In human cancer gene therapy, there
are still many problems, such as finding the right vector
for gene therapy. Significant effort has been expended in
establishing a stable and specific therapeutic gene vector
for expression in tumor cells that can be used in clinical
treatment. However, the technology is not mature yet.
Drugs for clinical experimental treatments synthesized
in vitro by chemical modification of an oligonucleotide are
expensive, have a short half-life and are sometimes cyto-
toxic especially when administered over a long period of
time. Transcriptional-level RNAi-induced gene silencing
not only regulates the degradation of homologous se-
quences but also induces heterochromatin formation,
DNA methylation and histone modification, so that the21 cells. (A) 48 h after TGS transfection. (B) 72 h after TGS transfection.
PTGS transfection. (c) 96 h after TGS transfection (d) Quantitation of the
Table 1 Number of SMCC-7721 cells migrated across the membrane after TGS and PTGS of heparanase
Time PTGS (mean ± standard deviation) TGS (mean ± standard deviation) Control (mean ± standard deviation)
48 h 3.33 ± 1.5* 1 ± 1* 14 ± 2.6
72 h 7.6 ± 1.5** 1.3 ± 0.68* 17 ± 1.5
96 h 12 ± 2.1 8.6 ± 1.5** 15 ± 1.3
*P < 0.05 and **P > 0.05 compared with the control group.
PTGS, post-transcriptional gene silencing; TGS, transcriptional gene silencing.
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the 5′ end promoter has been administered, the gene can
be permanently silenced. Therefore, there is a broad appli-
cation potential for RNAi at the level of transcription. This
study was a comparative study to compare the effect of
gene interference of TGS with that of PTGS to confirm
the superiority of TGS interference.
First, siRNAs that targeted the promoter region within
the nucleus were designed. Corresponding siRNAs tar-
geting the cytosolic mRNA region were also designed.
PCR analysis showed that genes for both of the two
groups of cells were silenced 48 h after siRNA transfec-
tion. However, at 72 h after siRNA transfection, the
interference seen in the PTGS group had significantly
decreased, while the interference seen in the TGS group
was still obvious. At 96 h after transfection, the interfer-
ence seen in the TGS group had declined as well. The
protein expression of heparanase was similar. Western
blot experiments showed that the silence time of hepara-
nase in cells from the TGS group was much longer than
that of the PTGS group. However, both the TGS and
PTGS groups showed slight inference at 96 h after trans-
fection. Wound healing and Transwell invasion assays
also proved that there was less invasion and migration of
cells for both the TGS and PTGS groups within 48 h of
transfection. At 72 h after transfection, the migration
and invasion capacity of the PTGS group had recovered
a little, while the TGS group showed no obvious diffe-
rence from the situation 24 h before. At 96 h after trans-
fection, the migration and invasion capability of cells in
the PTGS group had been restored significantly. Though
the TGS group expressed heparanase, the level was still
very low. In combination with the experimental results
above, a much longer silence time of heparanase was ob-
served in the TGS group with respect to the PTGS
group. However, TGS did not achieve a permanent gene
knockout as previously expected.
Although this study could not confirm a permanent
knockout of the heparanase gene for either the gene level
or protein levels, the silence time of heparanase for the
TGS group was longer than that of the PTGS group.
Wound healing and Transwell invasion assays also proved
that migration and invasion of the TGS cells were re-
duced. There was still a wide gap between our results andthe speculation that TGS may knock out gene expression
permanently. There are three possible reasons. The first is
the low efficiency of nuclear transfection. Only a few of
the siRNAs were transfected into the nuclei by electric
transfection and the majority of the siRNAs degraded in
the cytoplasm. This may have caused the unexpected re-
sults seen in our study. In preliminary experiments, ordi-
nary liposome transfection was used and there was almost
no interference after TGS while PTGS produced signifi-
cant genetic interference (data not shown), indicating
that effective nuclear transfection is important for TGS.
Second, different effects may have occurred because of the
different type of cells or genes used for TGS. Epigenetics
may affect the efficiency of nuclear transfection. Third,
gene expression controlled by epigenetics is reversible.Conclusions
We found that TGS could effectively interfere with the
heparanase gene to reduce the invasion and migration of
hepatoma SMCC-7721 cells, which is a very important
experimental basis for TGS research in cancer gene ther-
apy. The mechanism of TGS, as well as whether it is
more effective for the RNAi to target CpG islands or
transcription factor binding sites are still unknown. How
long can RNAi-induced epigenetic alterations be main-
tained? Whether CpG islands in genes are suitable as
the promoter of RNAi is still unclear. Therefore, further
research is needed for these problems.
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